GH secretagogue (most potent GHRP) · Cardioprotective peptide via CD36/GHS-R1b mechanism independent of GH
Administration
Subcutaneous injection · Intranasal (investigated) · IV (research)
Half-life
~30–60 minutes
Most studied use
Maximum GH release · Cardiac protection · Recovery · Body composition
Regulatory status
Not FDA-approved · Category 1 compound · Research chemical · Under investigation for cardiac protection
Human evidence
Good — multiple human PK/PD studies confirming GH potency; ex vivo human cardiac tissue CD36 activation confirmed; cardiac protection preclinical independently replicated
Preclinical evidence
Exceptional — most studied GHRP for cardiac protection; 30+ years of research
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is hexarelin?
Hexarelin occupies a unique position in the GH secretagogue space: it's simultaneously the most potent GH-releasing peptide in its class and the only GHRP with a well-characterized, GH-independent cardioprotective mechanism. Understanding both aspects is essential to understanding why hexarelin is more than just 'a stronger GHRP-6.'
On GH potency: hexarelin produces the highest acute GH peaks of any synthetic GHRP — higher than GHRP-2, GHRP-6, or ipamorelin at equivalent doses. This is attributed to its particularly high affinity for GHS-R1a (the ghrelin receptor) and its additional activity at hypothalamic receptors that suppress somatostatin. The trade-off is the same as with the other potent GHRPs: meaningful cortisol and prolactin elevation alongside GH. What differentiates hexarelin from GHRP-6 is that the appetite stimulation, while present, is somewhat less pronounced — hexarelin's hunger profile sits between ipamorelin's minimal hunger and GHRP-6's intense hunger.
On cardiac protection: hexarelin was discovered to activate CD36 (a scavenger receptor expressed in heart muscle) and GHS-R1b (a truncated ghrelin receptor isoform in cardiac tissue) through mechanisms completely independent of GH release. In multiple cardiac ischemia-reperfusion models, hexarelin reduced infarct size by 30–50% and preserved cardiac function. This cardiac mechanism was observed even in GH-deficient animals — confirming it's GH-independent. Hexarelin is the only GHRP that has been specifically studied for this cardiac application.
How it works
GHS-R1a Agonism — Maximum GH Release
Hexarelin binds GHS-R1a (ghrelin receptor) with exceptionally high affinity, producing the strongest acute GH release of the GHRP family. Like GHRP-2 and GHRP-6, it also acts at the hypothalamic level to stimulate GHRH release and suppress somatostatin — triple amplification of GH secretion. The modified tryptophan at position 2 (D-2-methyl-Trp) and the D-phenylalanine at position 5 contribute to both receptor affinity and protease resistance compared to earlier GHRPs.
CD36 and GHS-R1b — Cardiac Protection Independent of GH
Hexarelin's cardiac mechanism operates through CD36 (a multifunctional scavenger receptor in cardiomyocytes) and GHS-R1b (the truncated, non-signaling ghrelin receptor isoform that forms heterodimers with CD36 in cardiac tissue). Hexarelin binding to this CD36/GHS-R1b complex activates ERK1/2 and Akt survival signaling, upregulates anti-apoptotic Bcl-2, and reduces pro-apoptotic Bax — providing direct protection against ischemia-reperfusion injury. This mechanism is completely independent of GH release, confirmed in GH-deficient animals.
Cortisol, Prolactin, and Tachyphylaxis
Like GHRP-2 and GHRP-6, hexarelin produces cortisol and prolactin elevation through broad ghrelin receptor activation — similar in magnitude to GHRP-2. Daily use can produce tachyphylaxis (reduced GH response over time as GHS-R1a receptors desensitize) — less of an issue at 3x per week vs. daily dosing. Cycling and frequency management are important for maintaining GH response over longer protocols.
What the research shows
HUMAN EVIDENCE
STUDYClinical Endocrinology · 1995
Hexarelin dose-dependently stimulates GH secretion in healthy adults
Laron Z, Frenkel J, Deghenghi R et al.
Human dose-finding study. Hexarelin produced dose-dependent, sustained GH release in healthy men and women. Peak GH responses exceeded those of GHRP-6 at equivalent doses. Established hexarelin as the most potent GHRP in humans.
Hexarelin protects the heart via CD36 — human cardiac tissue study
Siddiqui MN et al.
Ex vivo human cardiac tissue study. Hexarelin activated protective signaling (ERK1/2, Akt) in human cardiomyocytes via CD36. First direct evidence that the cardiac mechanism operates in human cardiac tissue — confirming GH-independent cardiac protection.
Hexarelin reduces infarct size and preserves cardiac function after ischemia
Locatelli V et al.
Rat ischemia-reperfusion model. Hexarelin (pre-treatment and post-ischemia) reduced infarct size 30–50% and preserved LV function. Cardiac mechanism confirmed to be GH-independent. Multiple independent replications confirmed this finding.
✓GH-independent cardiac mechanism — confirmed in GH-deficient animals
✓Cortisol and prolactin elevation alongside GH — same as GHRP class
?UNCERTAIN
?Whether cardiac protection translates to meaningful human clinical outcomes (no RCT)
?Optimal dose for cardiac protection vs. GH release (different goals may require different doses)
?Long-term safety beyond research use durations
?Head-to-head vs. GHRP-2 for GH release and cardiac outcomes
What the community reports
—Strongest GH spikes of any injectable GHRP — consistently reported as exceeding GHRP-2 and GHRP-6 at comparable doses
—Significant GH flush and tingling — a distinct sensation of GH elevation noticed within 15–30 minutes of injection; useful early indicator of tachyphylaxis if diminishing
—Appetite increase present but moderate — less intense than GHRP-6; more than ipamorelin
—Cardiac protection framing: subset of users specifically choose hexarelin for its cardiac mechanism — post-MI recovery, cardiac optimization alongside GH benefits
—Tachyphylaxis: reduced GH response noted in some long-term daily users; 3x/week protocols avoid this more consistently than daily dosing
Common misconceptions
"Hexarelin is just a more potent GHRP-6."
REALITY
Hexarelin and GHRP-6 both activate GHS-R1a but hexarelin has additional CD36/GHS-R1b cardiac receptor activity that GHRP-6 does not. The cardiac protection mechanism is unique to hexarelin in the GHRP family and operates completely independently of GH release. More potent GH release + unique cardiac mechanism makes hexarelin mechanistically distinct, not just stronger.
"Hexarelin's cardiac effects are proven in humans."
REALITY
The CD36/GHS-R1b cardiac mechanism has been confirmed in ex vivo human cardiac tissue. The infarct reduction and functional preservation data is from rodent models. A human cardiac protection RCT has not been conducted. The mechanism operates in human cardiac tissue; whether it produces clinically meaningful cardiac protection in humans requires clinical trials.
"You can use hexarelin daily without concern."
REALITY
Daily hexarelin use can produce tachyphylaxis — reduced GH response over time as GHS-R1a desensitizes. Pulsatile, less frequent use (3x/week maximum) preserves receptor sensitivity. If the GH flush diminishes over weeks, take 2 weeks off before restarting.
GHRP FAMILY DECISION FRAMEWORK
Hexarelin: maximum GH + unique GH-independent cardiac protection (CD36/GHS-R1b). GHRP-2: maximum GH, no cardiac mechanism, classic CJC stack. Ipamorelin: clean selective GH with minimal cortisol or appetite. GHRP-6: maximum GH + intentional appetite for mass-building.
RECONSTITUTION CALCULATOR
EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN
AI COACH PREVIEW
I want maximum GH from a GHRP. Should I use Hexarelin or GHRP-2 + CJC-1295?
This is the right comparison to make, and the answer depends on whether the cardiac mechanism matters for you. Let me break both options down so you can make a protocol decision. Hexarelin solo or with CJC-1295: hexarelin produces the highest acute GH peaks of any synthetic GHRP — confirmed in human studies. The GH flush is real and typically noticeable within 15–30 minutes of injection. Hexarelin also activates CD36/GHS-R1b in cardiac tissue independently of GH — this is the unique mechanism no other GHRP has. In rodent ischemia models it reduced infarct size 30–50%; confirmed in ex vivo human cardiac tissue. Whether this produces meaningful cardiac protection in living humans hasn't been tested in an RCT. GHRP-2 + CJC-1295 (no-DAC): GHRP-2 produces slightly lower GH peaks than hexarelin but is well-established with decades of community data. The CJC-1295 component adds GHRH receptor stimulation, creating dual-receptor synergistic GH elevation — the combination produces meaningfully more GH than either alone. The CJC component is something hexarelin alone doesn't include, so hexarelin + CJC-1295 is actually the more apt comparison — and that combination rivals GHRP-2 + CJC in GH output. Tachyphylaxis consideration: hexarelin develops tolerance faster with daily use than GHRP-2 does. For either, 3x per week maximum preserves receptor sensitivity. If you're specifically interested in the cardiac protection aspect — post-cardiovascular event recovery, cardiac optimization, or running a GH protocol alongside existing heart concerns — hexarelin is the choice because it's the only GHRP with that mechanism. If you want maximum GH from a well-established protocol without the cardiac consideration, GHRP-2 + CJC-1295 has more community protocol data. Cortisol profile: both hexarelin and GHRP-2 produce similar cortisol elevation. The hunger effect with hexarelin is moderate — between ipamorelin's minimal and GHRP-6's intense. What's the primary goal — GH optimization for body composition, sleep/recovery, or specifically the cardiac mechanism?
CONTINUE IN THE APP
Open PepperLedger to build your Hexarelin protocol →
Free to join. No credit card. Ask the Coach about your GH secretagogue stack once you're in.
Free to join · No credit card · 23-day Pro trial included